patients previously treated with programmed cell death protein 1 (PD-1)-targeting
monoclonal antibodies for malignant pleural mesothelioma (MPM) and advanced non-small
cell lung cancer (NSCLC). In multiple mouse cancer models, de novo synthesis of
mevalonate and cholesterol inhibitors was found to synergize with anti-PD-1 antibody
therapy. In the present study, we investigated whether statins affect programmed death …